Background Angiotensin converting-enzyme (ACE) inhibitors used for the treatment of heart failure relieve symptoms, increase exercise performance, reduce hospital admissions and prolong life. The large survival studies have used higher doses of ACE inhibitors than those commonly used in clinical practice. NETWORK was set up to compare the effect of dose on the clinical outcome of ACE inhibition.
Introduction
Chronic heart failure affects approximately 1% of the total population and the prevalence increases with age to greater than 10% in those over 80 years [1, 2] . The prognosis is poor [3, 4] . Patients with heart failure or systolic dysfunction benefit from the addition of angiotensin converting-enzyme (ACE) inhibitors to conventional treatment with diuretics, with or without digoxin. Symptoms are relieved, exercise capacity increased, hospitalization reduced and life prolonged [5] [6] [7] [8] . There is uncertainty surrounding the mode of action of ACE inhibitors [9] , the optimum dose [10, 11] and the applicability of trial results to a wider population.
The target dose of enalapril in the large outcome studies in chronic heart failure was 20 mg twice daily in CONSENSUS [5] , 10 mg twice daily in SOLVD [6] and 20 mg daily in V-HeFT II [7] . In the context of heart failure or left ventricular dysfunction after myocardial infarction the target dose was captopril 50 mg three times a day in SAVE [12] , ramipril 5 mg twice daily in AIRE [13] and trandolapril 4 mg daily in TRACE [14] . The mean achieved dose of enalapril was 18·4 mg daily in CONSENSUS [5] and 16·4 mg daily in the treatment arm of SOLVD [6] . In the U.S.A. much lower doses of enalapril are commonly used for the treatment of heart failure, the mean daily dose of enalapril being 9 mg daily [15] . A study from the U.K. reported mean doses of enalapril 10 mg daily, captopril 37·5 mg daily and lisinopril 5 mg daily [16] . In hospital practice between 24% and 70% of patients treated for heart failure [17, 18] received the target dose of the mortality trials. Small trials have shown inconsistent results from low doses of ACE inhibitors with regard to symptoms, exercise capacity and the end-point of death or transplantation [10, 11, [19] [20] [21] [22] [23] [24] . The caution of clinicians in increasing the dose of an ACE inhibitor to the target doses in the large mortality trials may be a reflection of concern with regard to side-effects such as hypotension, reduced renal function, hyperkalaemia or cough. NETWORK was designed to investigate the dose response relationship of enalapril for the combined end-point of mortality, heart failure related hospitalization and worsening heart failure. Patients were recruited from general practice and hospitals (the NETWORK) with the intention of studying patients representative of the total heart failure population.
Methods
The rationale, organisation, and outcome definitions of NETWORK have been published [25] . NETWORK was a double-blind, randomized, parallel group study of 1532 patients with symptomatic heart failure comparing three doses of enalapril (2·5 mg, 5 mg and 10 mg twice daily) over a follow-up period of 6 months for each individual patient. The objective of the trial was to investigate the relationship between the dose of enalapril and the incidence of the primary end-point, mortality, heart failure related hospitalization or worsening heart failure. Other objectives were to establish how the diagnosis of heart failure in primary care correlated with that in a hospital setting and to assess the safety of enalapril in patients with symptomatic heart failure in relation to the use of enalapril in clinical practice.
Study design
The study was planned to recruit a spectrum of patients reflecting the demography of heart failure in the U.K. Patients who were likely to fulfil the inclusion criteria were referred from general practice or hospital clinics to the investigator. Patients entered a 2-week placebo run-in period during which the diagnosis of heart failure, adherence to the inclusion and exclusion criteria and the stability of symptoms, signs and treatment were established. The diagnosis of heart failure was confirmed by the hospital investigator on the basis of a clinical examination, chest X-ray, electrocardiogram and echocardiographic assessment. The inclusion criteria were age 18 to 85 years, a clinical diagnosis of heart failure, symptoms compatible with New York Heart Association (NYHA) Functional Class II to IV, an abnormality of the heart and current treatment for heart failure. No limits were set for heart size or the ejection fraction at entry. Patients with significant valvular disease, unstable angina, recent myocardial infarction, uncontrolled hypertension, hypotension, advanced pulmonary disease, serum potassium <3·2 mmol . l 1 or >5·5 mmol . l 1 , serum creatinine >200 mol . l 1 or contraindications to ACE inhibitors were excluded [25] . Patients were not previously on treatment with an ACE inhibitor.
All potential patients received a test-dose of enalapril 2·5 mg. After randomization to one of three groups, enalapril 2·5 mg was given once daily for 3 days. On days 4 to 7 inclusive, patients received 2·5 mg twice daily. Patients randomized to Group I remained on 2·5 mg twice daily throughout the study. Patients in Groups II and III had their dose increased to 5 mg twice daily after one week. Patients in Group III had their dose increased to 10 mg twice daily after a further week. Titration to the target dose was conducted double-blind. Blinded titration was continued provided that symptomatic hypotension did not occur, that systolic blood pressure was >80 mmHg without a postural fall >20 mmHg and that renal function did not deteriorate. If required, enalapril could be down-titrated, doubleblind. Patients were maintained at their maximum tolerated dose level for the remainder of the study. Patients were seen on a further six occasions for routine follow-up to assess symptoms, signs and adverse events during the 24-week treatment period for each patient in the study. Symptomatic efficacy was estimated from a dyspnoea/fatigue score [25] recorded at entry and at the final visit. Global assessments of outcome at the final visit were made independently by the investigator and patient on a five grade scale.
Organizational structure
Eighty two hospital centres and 610 general practitioners (the NETWORK) participated in the study. The protocol was approved by the local Ethics Committee at each centre and each patient gave informed consent. Randomization was undertaken centrally and eight monitors verified the data. The study was overseen by an independent Steering Committee, monitored by an independent Safety Committee and conducted to the standards of the European Directive on Good Clinical Practice. All potential end-points were reviewed by an End-points Committee who classified the events according to agreed definitions [25] .
Primary end-point and statistical considerations
The primary end-point was the first occurrence of a primary event of mortality, heart failure related hospitalization or worsening heart failure. Heart failure related hospitalization was defined as a hospital admission for worsening symptoms or signs of heart failure, for complications relating to the treatment of heart failure, for syncope or for arrhythmias [25] . Worsening heart failure was defined as increasing symptoms or worsening signs of heart failure and an increase in the baseline dose of frusemide by at least 40 mg (or equivalent), addition of a new vasodilator, addition of spironolactone, addition of a thiazide diuretic to a loop diuretic, or addition of digoxin (excluding the use of digoxin for atrial fibrillation). The presence of an event contributing to the primary endpoint was sought in all patients including patients who withdrew from the study.
The SOLVD study [6] suggested that at 6 months the incidence of the combined end-point of death and heart failure related hospitalization was 11% for enalapril treated patients and 20% for placebo treated patients. These figures were used to estimate the numbers required in this study based on three untested assumptions. First, patients are hospitalized more readily in the U.S.A. than in the U.K. Second, the outcome for the enalapril 2·5 mg twice daily group would be slightly better than for those on placebo in SOLVD. Third, the inclusion of worsening heart failure in the primary end-point would increase the number of endpoints, thereby compensating for the possible higher rate of hospitalization in the U.S.A. If 500 patients were enrolled into each treatment regime, the study had a greater than 85% power (P<0·05) to detect a reduction in the primary end-point from 18% in the 2·5 mg twice daily treatment group to 11% in the 10 mg twice daily treatment group. Analysis was by intention to treat.
Relative risks for the primary end-point in the three groups were calculated from the crude event rates. The hazard ratios were estimated using Cox regression. The estimated percentages of patients reaching the primary end-point are presented as a Kaplan-Meier plot. The principal analysis of interest was the comparison of the outcomes in the 2·5 mg twice daily and 10 mg twice daily treatment groups. Changes in the dyspnoea/fatigue index were assessed by analysis of variance. Global investigator and patient assessments were compared between groups by the Kruskal-Wallis chi-square test.
Results
A total of 2740 patients were referred from the NET-WORK, 1674 from general practice and 1066 from hospitals. Of these, 2499 attended for screening. Five hundred and sixty-six were excluded because the diagnosis of heart failure was not confirmed and 58 because other inclusion criteria were not fulfilled. One thousand, eight hundred and seventy-five entered the placebo run-in period. A total of 1566 patients received the test dose of enalapril. Of these 11 (0·7%) were not randomized solely on the grounds of not tolerating the test dose and 14 (0·9%) because they violated other exclusion criteria. Six patients died during the 2-week run-in period and six, who were not randomized, died within the following 70 days. Of the 1875 patients, 118 did not complete the placebo run-in period and a further 224 were not randomized. Thus, 1533 patients were randomized. Records for one patient were lost. The analysis is based on 1532 (1875-118-224-1) patients.
The baseline demographic data are shown in Table 1 . The mean age was 70 years and the ratio of males to females was 64:36. Coronary heart disease was the cause of heart failure in 71% of patients and 34% had had a Q wave infarct. Over 95% of patients were receiving diuretics for the treatment of heart failure, 65% were in NYHA class II and 24% had atrial fibrillation. There were no baseline differences between the three groups.
The maximum dose level achieved in the three groups is shown in Table 2 . The percentage of patients reaching the randomized dose level was 85% in Group III (10 mg twice daily) somewhat lower than the 96% in Group II (5 mg twice daily). The percentage of patients on study drug at the 24 week visit was less in Group III (73%) than in Group I (80%). Table 3 shows the number of patients reaching the primary end-point in each of the three treatment groups, the events contributing to the end-point and the number of primary events. The total number of patients reaching an end-point was 204 (13·3%). The total number of deaths in the 6 months period was 53 (3·5%). There were no significant differences between the groups. Figure 1 shows the percentage of patients reaching the primary end-point. The hazard ratio of a primary event in the 10 mg twice daily group compared to the 2·5 mg twice daily group was 1·20 (95% CI 0·86 to 1·68). The crude relative risk of a primary event in the same groups was 1·20 (95% CI 0·88 to 1·64).
In patients receiving 2·5, 5, or 10 mg twice daily of enalapril, respectively, the numbers of validated myocardial infarcts were two, six and five, the number of strokes four, two and five and the total hospitalizations 83, 80 and 93. The percentages of patients improving by one grade or more compared to baseline of the NYHA classification were 34, 33 and 31%. The percentages deteriorating by one NYHA grade were 5·3, 4·9 and 2·7%. The initial dyspnoea/fatigue index was 6·2 (SD 2·1), 5·9 (SD 2·2) and 6·1 (SD 2·1) at the start of the study and increased by 1·0 (SD 2·0, n=437), 1·1 (SD 2·0, n=446) and 1·2 (SD 2·1, n=444), respectively, at 24 weeks, indicating symptomatic improvement. The global assessment by the investigator categorized the response of the patient as very good or good in 56, 58 and 57% of patients and very poor or poor in 13, 15 and 16% of patients. The judgement of the patients was that they were much better or better in 66, 68 and 66% and much worse or worse in 9·1, 8·4 and 12·2%. None of these differences between the three groups were statistically significant.
The withdrawals from treatment are shown in Table 4 . Clinical or laboratory adverse events thought likely by the investigator to be related to the study drug occurred in Group I in 45·5% of patients, in Group II in 48·2% of patients and in group III in 52·1% of patients. In the three Groups (I to III respectively) the commonest drug-related adverse events by far were dizziness (19·6, 18·2, 20·2%), cough (15·4, 14·5, 13·8%) and fatigue (4·2, 7·5, 8·5%). The creatinine rose above 200 mol . l 1 on at least one occasion in 3·0, 5·3, and 5·8% of patients respectively and hyperkalaemia (potassium >5·2 mmol . l 1 ) occurred in 1·6, 2·2, and 3·3% of patients respectively.
Discussion

NETWORK was successfully completed according to the protocol but did not demonstrate the expected
The NETWORK Investigators 483 difference in the combined end-point of worsening heart failure, heart failure related hospitalization and death in patients taking enalapril 2·5 mg twice daily, 5 mg twice daily or 10 mg twice daily for a period of 6 months. In all groups, the change of NYHA class, the improvement in symptoms and the global assessment of health consistently indicated a clinical benefit. Enalapril was well tolerated and adverse events necessitating withdrawal of therapy were uncommon.
The predicted outcome and power of NET-WORK were based on the results of the treatment arm of SOLVD [6] . In that study enalapril was compared to placebo in 2569 patients with heart failure followed over a period of 41 months. The target dose of enalapril was 10 mg twice daily which was achieved in 49% of patients. The mean achieved daily dose of enalapril was 16·4 mg. The combined end-point of death or hospitalization at 6 months was 11% in the treated group and 20% in the LVEDD=left ventricular end diastolic dimension; BSA=body surface area. The equivalents for frusemide are based on the 1397 patients on diuretics for whom a frusemide equivalent could be estimated.
placebo group. In NETWORK the target dose was reached in 99%, 96% and 85% of patients randomized to receive enalapril 2·5, 5, 10 mg twice daily, respectively. In NETWORK an additional end-point was worsening heart failure. The primary end-point in the group of patients on the highest dose of enalapril 10 mg twice daily occurred in 15% of patients in NETWORK, slightly higher than that expected (cf 11% in SOLVD) indicating the patients in NETWORK had worse heart failure than those in SOLVD. The study therefore should have had sufficient end-points to demonstrate the anticipated result. In the low dose group (2·5 mg twice daily) the primary end-point occurred in 12% of patients (cf 20% in the placebo arm of SOLVD). Thus patients receiving the lowest dose of enalapril did not have a different outcome to patients on the highest dose.
One possible explanation for the findings in NETWORK is that the patient population differed from those of other trials. The patients in NETWORK were intentionally identified by a system that would encourage referrals from primary physicians so that the population of patients studied might as a consequence closely reflect the pattern of heart failure in the community. That goal was partly achieved since the mean age (70 years) and the proportion of females (36%) corresponds closely to that reported in epidemiological studies [2, 16] . In terms of age, the patients were almost 10 years older than those in other recent trials of ACE inhibitors [6, 7, 12, 13] , but similar to those in CONSENSUS, the first major study of ACE inhibitors on mortality in severe heart failure [5] . The severity of heart failure in NETWORK was similar to SOLVD since 65% were in NYHA class II (none in NYHA class I), the left ventricular end-diastolic diameter was 59 mm and 96% were on diuretics (cf in SOLVD 67% in NYHA I or II, ejection fraction 25% and 85% on diuretics). None of these differences provides a satisfactory explanation for the lack of a dose-response effect. An alternative interpretation is that the dose response for the primary end-point with enalapril is flat. A single dose of 2·5 mg of enalapril is known to inhibit plasma ACE activity for up to 24 h in patients with hypertension [26] . A dose of captopril as small as 1 mg has been shown to interact with a diuretic to induce an increased diuresis [27] . In small trials low doses of enalapril have been claimed to improve haemodynamics, increase exercise capacity, alleviate symptoms and impact on mortality [19] [20] [21] [22] 24] whilst in other studies a great benefit has been observed with higher doses [23] . Some caution is appropriate in applying the results of this study to current medical practice. Three large mortality trials with target doses of enalapril 20 mg daily have shown an impact on mortality [5] [6] [7] and there is a strong argument, therefore, that these target doses should be used in clinical practice; but they are not [15, 16] . The target doses in the mortality trials were equivalent to the highest dose in NETWORK. NETWORK was not a mortality trial but had a combined end-point and in comparison to the mortality trials included patients more widely representative of those with heart failure in the general population. Thus, the possibility exists that there is a difference in the dose of enalapril which improves mortality and the dose which confers a benefit in terms of symptoms. At present, physicians commonly choose to prescribe enalapril in a dose of 10 mg daily [15, 16] , which may represent a compromise between the desire to use an ACE inhibitor and a wish to avoid the complications of dizziness, electrolyte disturbance and declining renal function. It is also possible that only patients with more severe heart failure benefit from higher doses and that this is reflected in physician's prescribing habits. Two other studies are currently investigating whether the dose of an ACE inhibitor has an impact on mortality (ATLAS and ACHIEVE). A further question arises as to whether the greatest benefit in terms of health delivery is achieved by focussing on the escalation of the dose of drug to the target doses of the large mortality trials rather than an increased emphasis on the identification of patients suitable for treatment with this category of drugs.
